@entity32 ( @entity32 ) are a mainstay in the treatment of @entity32 and are among the most widely used drugs worldwide. They are anti-inflammatory, antipyretic, and analgesic and are prescribed as first choice for the treatment of @entity627 and, in general, @entity32 . The main limitation in using @entity32 consists in their side-effects, including gastrointestinal ulcerogenic activity and @entity5143 . The mechanism of action of these drugs is attributed to the inhibition of cyclooxygenase (COX), and, consequently, the conversion of @entity1426 into @entity2918 . It is hypothesized that the undesirable side-effects of @entity32 are due to the inhibition of @entity9859 (constitutive isoform), whereas the beneficial effects are related to the inhibition of @entity2247 (inducible isoform). @entity1426 can also be converted to @entity4443 (LTs) by the action of @entity1437 (5- @entity16911 ). LTC(4,) LTD(4,) and LTE(4) are potent bronchoconstrictors, whereas @entity8285 is chemotactic for leukocytes and plays an important role in the development of @entity344 by contributing to the inflammatory process. Thus, developing dual inhibitor compounds that will simultaneously inhibit COX and 5- @entity16911 could enhance their individual anti-inflammatory effects and reduce the undesirable side-effects associated with @entity32 , especially of the gastrointestinal tract. The most promising COX/5- @entity16911 inhibitor is @entity47179 ( @entity47179 ), now in Phase III clinical trials. This new approach will certainly help to unravel the mechanisms at the root of the undesirable effects of @entity32 and to develop safer @entity32 .

Dual inhibitors of XXXX . A new avenue in anti-inflammatory therapy?

@entity32 :: ('MESH:D007249', 'Disease') :: ['NSAIDs', 'inflammation', 'Nonsteroidal anti-inflammatory drugs', 'inflammatory disease'] @entity1437 :: ('240', 'Gene') :: ['5-lipoxygenase'] @entity8285 :: ('MESH:D007975', 'Chemical') :: ['LTB(4)'] @entity627 :: ('MESH:D012216', 'Disease') :: ['rheumatic disorders'] @entity4443 :: ('MESH:D015289', 'Chemical') :: ['leukotrienes'] @entity16911 :: ('4015', 'Gene') :: ['LOX'] @entity1426 :: ('MESH:D016718', 'Chemical') :: ['Arachidonic acid', 'arachidonic acid'] @entity2918 :: ('MESH:D011453', 'Chemical') :: ['prostaglandins'] @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal ulcers'] @entity9859 :: ('4512', 'Gene') :: ['COX-1'] @entity5143 :: ('MESH:D001986', 'Disease') :: ['bronchospasm'] @entity2247 :: ('4513', 'Gene') :: ['COX-2'] @entity47179 :: ('MESH:C088092', 'Chemical') :: ['ML3000', '[2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl]-acetic acid']
@entity1437 :: (240,Gene) :: ['cyclooxygenase and 5-lipoxygenase']
